Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.44 USD
-0.56 (-2.43%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $22.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Intellia Therapeutics, Inc. (NTLA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$69.86 | $144.00 | $29.00 | 203.74% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Intellia Therapeutics, Inc. comes to $69.86. The forecasts range from a low of $29.00 to a high of $144.00. The average price target represents an increase of 203.74% from the last closing price of $23.00.
Analyst Price Targets (22)
Broker Rating
Intellia Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.52 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 26 recommendations.
Of the 27 recommendations deriving the current ABR, 19 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70.37% and 7.41% of all recommendations. A month ago, Strong Buy made up 69.23%, while Buy represented 7.69%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NTLA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 19 | 18 | 18 | 18 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 6 | 6 | 6 | 6 | 6 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.52 | 1.52 | 1.54 | 1.54 | 1.54 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/16/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
8/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/9/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
8/9/2024 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
8/8/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Moderate Buy |
7/11/2024 | SVB Securities | Mani Foroohar | Strong Buy | Strong Buy |
6/27/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
6/10/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/4/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Strong Buy | Strong Buy |
5/10/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Hold | Hold |
5/9/2024 | JMP Securities | Silvan C Tuerkcan | Hold | Hold |
4/23/2024 | Wedbush Securities | David M Nierengarten | Hold | Hold |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/1/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
2/23/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/23/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Hold |
2/15/2024 | Not Identified | Not Identified | Not Available | Hold |
1/2/2024 | Robert W. Baird & Co. | Jack K Allen | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.52 |
ABR (Last week) | 1.52 |
# of Recs in ABR | 27 |
Average Target Price | $69.86 |
LT Growth Rate | 1.10% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -1.38 |